|
|
|
|
Vol. 62, Issue 3, 539-544, September 2002
Departments of Ophthalmology and Neuroscience, The Johns Hopkins
University School of Medicine, Baltimore, Maryland
Nitric oxide (NO) promotes retinal and choroidal
neovascularization, although different isoforms of nitric-oxide
synthetase (NOS) are critical in each. Deficiency of endothelial NOS
(eNOS) suppresses retinal but not choroidal neovascularization, whereas deficiency of neuronal NOS (nNOS) or inducible NOS (iNOS) suppresses choroidal, but not retinal neovascularization. In this study, we
investigated the effect of
NG-monomethyl-L-arginine
(L-NMMA), a nonspecific NOS inhibitor, in three models of
ocular neovascularization. Oral administration of L-NMMA
caused significant inhibition of choroidal neovascularization in mice
with laser-induced rupture of Bruch's membrane and significantly inhibited subretinal neovascularization in transgenic mice with expression of vascular endothelial growth factor (VEGF) in
photoreceptors (rho/VEGF mice) but did not inhibit retinal
neovascularization in mice with ischemic retinopathy. By extensive
mating among mice deficient in NOS isoforms, triple homozygous mutant
mice deficient in all three NOS isoforms were produced. These mice had
marked suppression of choroidal neovascularization at sites of rupture of Bruch's membrane and near-complete suppression of subretinal neovascularization in rho/VEGF mice but showed no difference in ischemia-induced retinal neovascularization compared with wild-type mice. These data indicate that NO is an important stimulator of choroidal neovascularization and that reduction of NO by pharmacologic or genetic means is a good treatment strategy. However, the situation is more complex for ischemia-induced retinal neovascularization for
which NO produced in endothelial cells by eNOS is stimulatory, but NO
produced in other retinal cells by iNOS and/or nNOS is inhibitory.
Selective inhibitors of eNOS may be needed for treatment of retinal neovascularization.
This article has been cited by other articles:
![]() |
H. She, T. Nakazawa, A. Matsubara, T. Hisatomi, T. A. Young, N. Michaud, E. Connolly, A. Hafezi-Moghadam, E. S. Gragoudas, and J. W. Miller Reduced Photoreceptor Damage after Photodynamic Therapy through Blockade of Nitric Oxide Synthase in a Model of Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., May 1, 2007; 48(5): 2268 - 2277. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Nambu, R. Nambu, M. Melia, and P. A. Campochiaro Combretastatin A-4 Phosphate Suppresses Development and Induces Regression of Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3650 - 3655. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Kozak and A. Kozak Genetic Models in Applied Physiology: Selected Contribution: Differential role of nitric oxide synthase isoforms in fever of different etiologies: studies using Nos gene-deficient mice J Appl Physiol, June 1, 2003; 94(6): 2534 - 2544. [Abstract] [Full Text] [PDF] |
||||